A Trial to Determine the Efficacy and Safety of Presendin in IIH

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
Idiopathic intracranial hypertension (IIH) has significant associated morbidity and reduced quality of life. There is a significant risk of visual loss and patients also typically suffer with chronic disabling headaches. This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.
Epistemonikos ID: fd1c41a10be695dbb7b958c6722b67b73482fcfa
First added on: Oct 02, 2023